Viva In Vitro intends to start testing its beta prototype by the end of 2022. This will allow to verify the usability conditions in realistic conditions and ensure final design specifications meet the expectations of the numerous users and potential buyers in hospitals throughout Spain who were consulted before starting the development of the product. The goal is to get the definitive prototype by the end of 2023.
The generation of independent clinical evidence among opinion leaders in the clinical setting would start immediately after that.
In parallel to the technical and clinical aspects, the regulatory will be addressed too, quality manual (QMS) and product dossier, in order to obtain Viva In Vitro ISO 13485 certification for and the device CE mark during in the year 2024.
